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ABSTRACT
Objective: This study aimed to investigate the effects of multiwalled carbon nanotubes (MWNTs) co-delivering
sorafenib (Sor) and epidermal growth factor receptor (EGFR) siRNA (MWNT/Sor/siRNA) on tumor growth in liver
cancer (LC).
Results: MWNT/Sor/siRNA was proved to possess increased Sor release, high siRNA stability, and enhanced
cellular uptake. In addition, MWNT treatment has few effects on cell proliferation and apoptosis in HepG2 cells;
however, MWNT/Sor/siRNA treatment significantly inhibited clone number and induced cell apoptosis, which
shows a more favorable antitumor effect than MWNT/Sor and free Sor and free siRNA in HepG2 cells.
Moreover MWNT/Sor/siRNA treatment has the most significant antitumor effect in vivo.
Conclusions: MWNT/Sor/siRNA exhibited a superior antitumor effect in vitro and in vivo.
Methods: The MWNT/Sor and MWNT/Sor/siRNA were prepared, and then the morphologies of MWNT/Sor/
siRNA were analyzed. In vitro Sor release assay, siRNA stability and cellular uptake of MWNT/Sor/siRNA were
performed as well. Next, the effects of MWNT, free Sor, free siRNA, MWNT/Sor and MWNT/Sor/siRNA were
evaluated by colony-forming assay, and cell apoptosis assay in HepG2 cells. Meanwhile, the level of EGFR and
proteins associated with apoptosis was tested. Furthermore, the anti-tumor effects of MWNT/Sor/siRNA on LC
xenograft mice were also unraveled.

INTRODUCTION
As one of the common malignant tumor, liver cancer
(LC) usually originates from the epithelial or
mesenchymal tissue of the liver [1]. LC statistics
estimated that approximately 364800 newly diagnosed
LC and 318800 death caused by LC were reported in
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2014 in China [2]. Early diagnosis and effective
treatment are effective methods to prevent further
deterioration of LC and death [3]. Nowadays, study has
reported the intensive progress in the diagnosis and
treatment of LC, which contributes to the decreasing
mortality and morbidity worldwide [3, 4]. Unfortunately,
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despite surgery, chemotherapy and radiotherapy are
effective therapeutic methods for early-stage LC, poor
prognosis still exists in metastatic LC [5], and the side
effects and drug resistance caused by chemotherapy
drugs greatly limit its clinical use [6]. Therefore, it is
essential to reveal the mechanisms of liver carcinogenesis
and search for novel therapeutics for LC.
Sorafenib (Sor) as a common multi-target kinase
inhibitor can be tailored to suppress cancer-associated
pathways, which has been widely and clinically applied
into the treatment of various cancers. However, the
clinical applications of Sor is restricted for effective
cancer treatment because of the low bioavailability,
nonspecific cytotoxicity leads to drug resistance and
other side-effects [7]. Thus, increasing researches
attempt to design a new Sor-loaded drug delivery
system to improve the concentration of Sor in tumor [8,
9]. Notably, accumulating evidence has demonstrated
that the receptor tyrosine kinase-epidermal growth
factor receptor (EGFR), is overexpressed in several
cancers [10, 11]. Specific inhibition of EGFR
expression is able to oppose cell proliferation and
induce apoptosis through reducing epidermal growth
factor activity, thereby it is considered as an ideal target
for gene therapy in cancers [12, 13]. Thus, combination
therapy of Sor and targeting EGFR may be potentially
powerful therapeutic strategy for LC.
Currently, carbon nanotubes (CNTs), particularly,
multiwalled carbon nanotubes (MWNTs) are reported to
be one class of highly attractive nanomaterials, and
displayed great biomedicine application values due to
exceptional physicochemical properties [14]. The
unique properties of MWNTs such as large specific
surface area as well as high stability and flexibility
contribute to the ability to carry more drug payloads and
high biocompatibility; thus, MWNTs have been
demonstrated to be a promising and meaningful drug
delivery system [15].
In the current study, we developed MWNTs co-delivering
Sor and EGFR siRNA (MWNT/Sor/siRNA), and then
characterization was detected. In addition, the functions of
MWNT/Sor/siRNA on cellular uptake, cell proliferation,
and apoptosis were measured in HepG2 cells. What’s
more, the anti-tumor functions of MWNT/Sor/siRNA on
LC xenograft mice were unraveled.

and visible tubular structure (Figure 1B, 1C). In
addition, the optical absorption spectra of MWNT/Sor/
siRNA revealed around 260 nm of absorption peaks
(Figure 1D). In addition, agarose gel retardation assay
showed that the electrophoretic mobility of MWNT/Sor/
siRNA complexes was significantly inhibited when the
N/P ratio of MWNT/Sor to siRNA was 1:1, and an
extremely low level of siRNA was found at 2:1 (Figure
1E). Then, the electrophoretic migration was ceased
when the N/P ratio was ≥ 4:1, which suggested almost
all the siRNA was integrated with MWNT/Sor (Figure
1E). The Sor drug LC and EE in MWNT/Sor/siRNA
were 8% and 85%, respectively, which indicated that
MWNT was suitable for Sor delivery and highly
entrapped within the MWNT. Moreover, the amount of
Sor released from MWNT/Sor and MWNT/Sor/siRNA
was measured at pH 7.4 and pH 5.0. Cumulative drug
release profiles showed that both MWNT/Sor and
MWNT/Sor/siRNA exhibited a burst release of Sor
within 5 h and a slow release from 5 h to 24 h at pH 7.4
and pH 5.0. Notably, about 80% of Sor was released
from both MWNT/Sor and MWNT/Sor/siRNA within
24 h at pH 5.0, which was faster than that at pH 7.4.
siRNA stability in MWNT/Sor/siRNA
Agarose gel retardation assay showed that at higher
RNase concentration, naked siRNA was quickly and
completely degraded; however, siRNA-encapsulated
MWNT/Sor/siRNA exhibited complete siRNA band
(Figure 2), which suggested that MWNTs could protect
siRNA against degradation.
Cellular uptake study
We found the enhanced fluorescence intensity for
siRNA and C6 based on confocal imaging analysis
when HepG2 cells were treated with MWNT/C6/siRNA
in time-dependent manner, especially, the fluorescence
intensity at 4 h is the strongest (Figure 3A). In addition,
when HepG2 cells were co-treated with MWNT/C6/
siRNA and inhibitors, the relative uptake efficiency
of MWNT/C6/siRNA was obviously inhibited by
the addition of colchicine, biotechnology fulvic acid,
filipin, sodium azide, M-β-CD, and nocodazole (Figure
3B), which indicated that MWNT/C6/siRNA entered
into cells through cellular cavitation and lipid raftmediated endocytosis, and the Golgi complex was
involved in endocytosis process.

RESULTS
Characterization of MWNT/Sor/siRNA

In vitro anti-proliferation effect of MWNT/Sor/
siRNA on HepG2 cells

Commercial carboxyl-MWNTs exhibited black
appearance (Figure 1A). Both SEM and TEM images
showed that MWNT/Sor/siRNA exhibited the complete

Firstly, western blot showed that the protein of EGFR
was significantly inhibited after HepG2 cells treated with
free siRNA or MWNT/Sor/siRNA (Figure 4A). Then,

www.aging-us.com

1873

AGING

using apoptosis and proliferation to test the antitumor
function of MWNT/Sor/siRNA on HepG2 cells. Colony
formation results revealed that HepG2 treated with PBS
exhibited similar colony formation with HepG2 cells
treated with MWNT, while the clone formation was
reduced after free siRNA or free Sor treatment (Figure
4B). Compared with free siRNA or Sor, the colony
formation was remarkably decreased treated with
MWNT/Sor, and cells treated with MWNT/Sor/siRNA
showed the lowest clone number (Figure 4B). Then, flow

cytometry revealed that the free siRNA or free Sor
significantly increased the rate of apoptotic cells
compared with control cells or cells treated with MWNT;
meanwhile, and compared with HepG2 cells with free
siRNA or free Sor, cells treated with MWNT/Sor showed
a higher rate of apoptosis, and then MWNT/Sor/siRNA
further increased the apoptotic rate (Figure 4C).
Meanwhile, the apoptosis-associated proteins were
detected by western blot. We found that free siRNA or

Figure 1. Characterization of MWNT/Sor/siRNA. (A) The representative images of MWNT/Sor/siRNA using scanning electron
microscope. (B) The representative images of MWNT/Sor/siRNA using transmission electron microscopy. (C) The ultraviolet visible absorption
spectra of MWNT/Sor/siRNA. (D) Gel retardation assay of naked siRNA and MWNT/Sor/siRNA complexes with the different N/P ratio. (E)
Cumulative drug release profiling of MWNT/Sor and MWNT/Sor/siRNA in PBS (pH 7.4 and pH 5.0).

www.aging-us.com

1874

AGING

free Sor treatment increased the protein levels of Bax,
Bid, Bim, cleaved caspase-3, and cleaved caspase-9,
while inhibited Bcl-2 level (Figure 4D). In addition,
compared with siRNA or free Sor treatment group,
MWNT/Sor or MWNT/Sor/siRNA treatment further
promoted the protein levels of Bax, Bid, Bim, cleaved
caspase-3, and cleaved caspase-9, and inhibited the Bcl2, especially MWNT/Sor/siRNA treatment (Figure 4D).

level of EGFR was significantly inhibited in siRNA and
MWNT/Sor/siRNA groups (p < 0.05, Figure 5D).
Meanwhile, Ki67 expression trend in various groups
was consistent with the tumor weight of mice (Figure
5D), These results revealed the better anti-tumor
function of MWNT/Sor/siRNA on LC xenograft mice.

In vivo anti-tumor function of MWNT/Sor/siRNA on
LC xenograft mice

In our present study, we prepared MWNT/Sor and
MWNT/Sor/siRNA. MWNT/Sor/siRNA was proved to
possess increased Sor release, high siRNA stability, and
enhanced cellular uptake. In addition, compared with
control group, MWNT treatment has few impact on cell
proliferation and apoptosis in HepG2 cells; however,
MWNT/Sor/siRNA treatment significantly inhibited
clone number and induced cell apoptosis, followed by
MWNT/Sor and free Sor and free siRNA in HepG2
cells. Similarly, in vivo experiments demonstrated that
the tumor volume and weight of LC xenograft mice
were obviously reduced after Sor or siRNA treatment
and which were further reduced in MWNT/Sor and
MWNT/Sor/siRNA groups, especially in MWNT/Sor/
siRNA group.

Xenograft mice study showed that the body weight of
mice in each group, including saline solution (control),
MWNTs, siRNA, Sor, MWNT/Sor, and MWNT/Sor/
siRNA, were similar (Figure 5A). The tumor volume of
LC xenograft mice was decreased after free siRNA or
free Sor treatment compared with control or MWNT
group, the tumor volume was reduced in MWNT/Sor
and MWNT/Sor/siRNA groups, especially in MWNT/
Sor/siRNA group (Figure 5B). Moreover, the tumor
weight was the lowest in MWNT/Sor/siRNA group,
followed by MWNT/Sor, Sor, and siRNA groups
(Figure 5C). Furthermore, IHC showed that the protein

DISCUSSION

Figure 2. Stability of naked siRNA and MWNT/Sor/siRNA after treated with RNase by gel retardation assay.
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Sor as a common chemotherapeutic drugs, has been
widely used for the clinical applications of metastatic
breast cancer [16], metastatic thyroid cancer [17], nonsmall cell lung cancer [18], advanced LC [19] and other
various cancers. Here, free Sor significantly inhibited
clone number, and increased the apoptotic rate of

HepG2 cells. Moreover, the protein levels including
Bim, Bad, Bax, Bcl-2, cleaved caspase-3, cleaved
caspase-9, were measured in this study. The bcl-2
family regulates the process of apoptosis, which is
essential for development, tissue homeostasis and
immune response [20]. It has been reported that Bcl-2

Figure 3. Cellular uptake of MWNT/Sor/siRNA by HepG2 cells. (A) Confocal images of HepG2 cells treated with for 0.5, 1 and 4 h,
respectively. (B) The relative uptake efficiency of MWNT/C6/siRNA after HepG2 cells treated with different inhibitors. *P < 0.05, **P < 0.01,
***P < 0.001 compared to control.
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Figure 4. MWNT/Sor/siRNA inhibited growth of HepG2 cells. (A) The protein expression of epidermal growth factor receptor (EGFR)
in HepG2 cells treated with PBS (control), MWNTs, siRNA, Sor, MWNT/Sor, or MWNT/Sor/siRNA by western blotting. (B) Colony number of
HepG2 cells in control group, MWNTs, siRNA, Sor, MWNT/Sor, or MWNT/Sor/siRNA detected by colony formation assay. (C) Cell apoptosis
rate of HepG2 cells in control group, MWNTs, siRNA, Sor, MWNT/Sor, or MWNT/Sor/siRNA tested by flow cytometry assay. (D) The proteins
expression including Bax, Bid, Bim, cleaved caspase-3, and cleaved caspase-9, in HepG2 cells in control group, MWNTs, siRNA, Sor,
MWNT/Sor, or MWNT/Sor/siRNA measured by western blot. *P < 0.05.
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family proteins regulate mitochondrial outer membrane
permeability and affect mitochondrial apoptosis [21].
As a key molecule of apoptosis pathway, caspase-3
inhibits Bcl-2/Bax ratio and promotes apoptosis. [21].

Moreover, when caspase-3 is activated, it can recruit
activated caspase-9 to play a role. [22]. Furthermore,
our xenograft model also revealed the anti-tumor
function of Sor on LC, which has been supported by

Figure 5. MWNT/Sor/siRNA showed better anti-tumor function in liver cancer xenograft mice. (A) The body weights of mice in
different groups, including saline solution (control), MWNTs, siRNA, Sor, MWNT/Sor, or MWNT/Sor/siRNA, respectively, every 3 days for 28
days. (B) The tumor volumes of control, MWNTs, siRNA, Sor, MWNT/Sor, or MWNT/Sor/siRNA, respectively, every 3 days for 28 days. (C) The
tumor weights of different treated mice on 28 days. (D) The expression of EGFR and Ki67 in tumor tissues of mice with different groups on 28
days by immunohistochemistry. *P < 0.05; **P < 0.01. Definition of the groups: No. 1: control, No. 2: MWNTs, No. 3: siRNA, No.4: Sor, No. 5:
MWNT/Sor, No. 6: MWNT/Sor/siRNA.
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previous clinical trials [23, 24]. Similarly, this study
found that free EGFR siRNA effectively inhibited
EGFR expression, and also obviously reduced cell clone
number and induced apoptosis in HepG2 cells.
Consistent with our results, previous studies have
shown that EGFR siRNA exhibited anti-tumor effect in
non-small cell lung cancer [25] and breast cancer [26].
However, the clinical application of many hydrophobic
anticancer drugs in cancer treatment is limited due to
poor water solubility. In addition, silence effect of
siRNA is also compromised by the instability of siRNA.
Fortunately, delivery efficiency of drug or siRNA has
been greatly improved when enveloped by nanomaterials. Wang et al. [27] have demonstrated that Sorloaded lipid nanoparticles can inhibit tumor growth of
liver cancer in vitro and in vivo. Another in vivo
experiment has also shown that Sor-loaded nanocapsule
also significantly suppress the development of
hepatocellular carcinoma [28]. Moreover, EGFR siRNA
loaded cationic glyco-nanogels enhance the EGFR
knockdown efficacy in ovarian cancer cells [29]. EGFR
siRNA enveloped nanocomplex also successfully
silence the expression of EGFR, and exhibited antitumor effect in head and neck cancer cells [30]. Herein,
Sor and/or siRNA were loaded into the MWNTs aimed
at better improve drug and siRNA deliver. Similar with
existing researches, our research also suggested that
compared with free Sor or siRNA, MWNT/Sor
significantly weaken cell proliferation ability and
resulted in cell apoptosis in HepG2 cells, and exhibited
enhanced anti-tumor function on LC xenograft mice.
Notably, MWNT/Sor/siRNA exhibited superior antitumor effect than MWNT/Sor. These results appeared
the synergistic anti-tumor function of co-delivery of Sor
and siRNA by MWNTs in vitro and in vivo.
Summing up, this study successfully developed
MWNT/Sor/siRNA, and MWNT/Sor/siRNA had a
superior tumor-inhibiting effects than MWNT/Sor in
vitro and in vivo. Overall, MWNT/Sor/siRNA might be
a promising therapeutic nanomedicine for LC targeting
therapy.

MATERIALS AND METHODS
Preparation of MWNT/Sor and MWNT/Sor/siRNA
Carboxyl-MWNTs were purchased from XFNANO
Materials Tech Co. Ltd (Nanjing, Jiangsu, China). The
MWNT/Sor was prepared as described below. In brief,
1 mg sorafenib and 1 mg MWNTs were dissolved in 1
mL of absolute ethyl alcohol by ultrasound for 1 h.
Then, the solution was centrifuged at 12000 rpm for 15
min, and precipitation was collected to mix with 8 mg
of PVPK30 and 8 mg of soybean lecithin in 1 mL of
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double distilled water by ultrasound for 1 h. After
centrifuged at 3000 rpm for 5 min, then supernatant was
transferred to 1.5 mL EP tube, and 15 mg of DOTAP
was added into supernatant. Lastly, MWNT/Sor was
obtained by ultrasound for 2 h. In addition, siRNA
targeted to EFGR gene (sense: 5’-GUGUGUAACGG
AAUAGGUATT-3’; and antisense: 5’-UACCUAUU
CCGUUACACACTT-3’) was incubated with MWNT/
Sor for 40 min at room temperature, thereby obtaining
MWNT/Sor/siRNA.
Agarose gel retardation assay
The siRNA loading efficiency of MWNT/Sor/siRNA
were by observed agarose gel retardation assay. Briefly,
the complexes of MWNT/Sor and siRNA with a N/P
ratio of 1:1, 2:1, 4:1, 6:1, and 8:1 as well as naked
siRNA were subjected to electrophoretic analysis with
0.8% agarose gel (100 V, 30 min), and then observed by
a UV transilluminator at 245 nm.
Characterization of MWNT/Sor/siRNA
The morphology of MWNT/Sor/siRNA was observed
by scanning electron microscope (SEM; SU3800;
Hitachi, Japan) and transmission electron microscopy
(TEM; HT7700; Hitachi, Japan). The ultraviolet (UV)
visible spectra of MWNT/Sor/siRNA was tested by UV
visible light absorption spectroscopy (Jasco, UK).
Detection of encapsulation efficiency (EE) and
loading capacity (LC)
MWNT/Sor was dissolved in methyl alcohol, and then
concentration of Sor was measured by high performance
liquid chromatography (HPLC). Sor was detected at
wavelength of 250 nm and flow velocity of 1.0 mL/min.
The formulas for LC and EE are as follows: EE% = Wt /
Ws × 100% and LC% = Wt / Wo × 100%.
Analysis of drug release in vitro
The drug release profiles of Sor from MWNT/Sor and
MWNT/Sor/siRNA at various pH were measured. In
short, 200 μL of MWNT/Sor and MWNT/Sor/siRNA
were put in dialysis bags respectively, and dialysis bag
was soaked in PBS (35 mL, pH 7.4 or 5.0, respectively).
The dialysis system avoids light shaking at a speed of
100 rpm in a constant temperature agitator at 37° C.
Then, dialysate (1 mL) was taken at 0.5, 1, 2, 3, 4, 6, 8,
12, 24, 36, 48, 72, and 96 h, respectively. Finally, the
Sor concentration was measured by HPLC.
Chromatographic conditions: use phenomenex C8
column (250 mm × 4.6 μm × 5 μm), mobile phase:
triethylamine phosphoric acid buffer (990 mL pure water,
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10 mL triethylamine added, pH adjusted to 5.4, detection
wavelength 250 nm, flow rate: 1.0 mL/min. The
concentration of sorafenib was in the range of 200.17480.41 μg/mL, showing a good linear relationship with
the peak area (r= 0.9998), and the lowest detection limit
was 0.1 ng.
siRNA stability assay
To evaluate the protective effect of MWNT/Sor/siRNA
on siRNA against RNase, equivalent MWNT/Sor/
siRNA or free siRNA were mingled with 1 µL RNase A
(1 mg/mL) at 37° C. Afterwards, these samples were
acquired at 0, 15 and 30 min, followed by immediate
refrigeration at -80° C. Lastly, the siRNA stability was
analyzed with 2% agarose gel.
Cell culture
HepG2 were provided by Procell (Wuhan, China), and
cultured in DMEM (Gibco) with 10% FBS (Gibco)
under 37° C and 5% CO2.

Apoptosis assay
FITC-Annexin V Apoptosis kit (BD Biosciences) was
used for apoptosis analysis. HepG2 cells were treated
according to the above design. Trypsin was used to
digest rat chondrocytes. The cells were resuscitated in
the buffer and incubated with FITC-conjugated Annexin
V and PI for 15 min, then cells were detected by flow
cytometry (BD, CA, USA).
Western blot assay
HepG2 cells were treated according to the above
design. The protein samples were transferred to PVDF
after electrophoresis on PAGE gel. The membrane
was then blocked and the first antibody to Bax, Bid,
Bim, Bcl-2, cleaved-caspase-3, cleaved-caspase-9,
EGFR or actin (1:200, Santa Cruz) was reacted
overnight at 4° C. Protein levels were detected by ECL
(Millipore, America) after incubation of the second
antibody.
Animals

Cellular uptake assay
As described above, coumarin C6 dye (green) was
instead of sorafenib to prepare MWNT/C6/siRNA, and
siRNA was labeled with cy5.5 dye (red). Briefly,
HepG2 were seeded in 35 mm dishes for 24 h, then
maintained with MWNT/C6/siRNA at 37° C for 0.5, 1
and 4 h, respectively. Then cells were fixed with 4%
paraformaldehyde solution for 15 min, and observed
using confocal fluorescence microscope.
Cellular uptake mechanism analysis
HepG2 cells were inoculated for 24 h in the culture
plate, and then incubated with 100 μl of 10 μg/mL
chlorpromazine, 4 μg/mL colchicine, 10 μg/mL
cytochalasin D, 5 μg/mL biotechnology fulvic acid, 2.5
μg/mL genistein, 5 μg/mL filipin, 100 mM/mL sodium
azide, 50 mM/mL deoxyglucose, 2.5 mM/mL M-β-CD,
200 nM/mL monensin and 20 μM/mL nocodazole for 1
h. Afterwards, cells were maintained with
MWNT/Sor/siRNA for 1 h and the cell uptake was
terminated with cold PBS. Meanwhile, cells without
any inhibitors were served as control. Cells were
collected and quantitatively detected by flow cytometry.
Colony formation assay
HepG2 were grown in 6-well plates, and then
respectively treated with PBS, MWNTs, siRNA, Sor,
MWNT/Sor, or MWNT/Sor/siRNA with the Sor dose of
20 μM for 14 days. Cells were stained with crystal
violet to calculate colony number.
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Approval from the Nanchang University Animal Ethics
Committee of the animal laboratory center was
obtained. Nude mice (Charles River, Beijing, China)
were used. 1 × 106 of HepG2 cells per mouse were
inoculated subcutaneously for mice xenograft model.
LC xenograft mice were intravenously treated with
saline solution (control group, n = 4), MWNTs (n = 4),
siRNA (n = 4), Sor (n = 4), MWNT/Sor (n = 4), or
MWNT/Sor/siRNA (n = 4), respectively. The drug
dosage is 40 mg/kg and administered every other day.
The body weight and tumor volume were tested every 3
days for 28 days. On day 28, after euthanized mice, the
weight of the tumor was measured.
Immunohistochemistry
Tumor tissues underwent formalin-fixation, paraffin
embedding, and slice preparation. After deparaffinization
and dehydration, the sections were treated with citrate
buffer (pH 6.0), followed by the heat pretreatment at
80° C and blocking with endogenous peroxide. Next,
the sections were incubated with Ki67 or EGFR
antibody, followed by the incubation of second
antibody. The sections were fixed with neutral resin and
observed under light microscope (Nikon, ECLIPSE CI).
The collected images were analyzed by Image-Pro Plus
6.0 software.
Statistical analysis
Data were presented as the mean ± SD. One-way
ANOVA followed by multiple comparison was used
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based on SPSS software. P < 0.05 was considered
significant.
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